Details of the Drug

General Information of Drug (ID: DM3BH1Y)

Drug Name
Lapatinib
Synonyms
FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 581.1
Topological Polar Surface Area (xlogp) 5.1
Rotatable Bond Count (rotbonds) 11
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 14.2 hours [4]
Metabolism
The drug is metabolized via the CYP3A4 and CYP3A5, with minor contributions from CYP2C19 and CYP2C8 to a variety of oxidated metabolites [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 30.73146 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.001 mg/mL [3]
Chemical Identifiers
Formula
C29H26ClFN4O4S
IUPAC Name
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
Canonical SMILES
CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
InChI
InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChIKey
BCFGMOOMADDAQU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
208908
ChEBI ID
CHEBI:49603
CAS Number
231277-92-2
DrugBank ID
DB01259
TTD ID
D08CDI
VARIDT ID
DR00120
INTEDE ID
DR0917
ACDINA ID
D00351

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [7], [8]
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Inhibitor [7], [8]
Eukaryotic elongation factor 2 kinase (eEF-2K) TT1QFLA EF2K_HUMAN Inhibitor [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5)
Main DME 		DEIBDNY CP3A5_HUMAN Substrate [13]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Epidermal growth factor receptor (EGFR) DTT EGFR 5.84E-05 0.32 0.55
P-glycoprotein 1 (ABCB1) DTP P-GP 1.42E-02 -2.10E-01 -5.11E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 1.07E-06 -3.94E-01 -6.94E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 2.90E-11 -1.06E-01 -1.42E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 2.45E-13 -2.29E+00 -1.44E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.49E-08 -1.53E-01 -6.35E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.04E-04 -9.90E-02 -3.91E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lapatinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Eribulin. Breast cancer [2C60-2C6Y] [80]
Talazoparib DM1KS78 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [81]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Lapatinib caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [82]
LY2835219 DM93VBZ Moderate Decreased metabolism of Lapatinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [83]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Lapatinib caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Tucatinib DMBESUA Major Decreased metabolism of Lapatinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [85]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Lapatinib caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Lapatinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [86]
⏷ Show the Full List of 8 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Lapatinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Lapatinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [85]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Lapatinib and Ivosidenib. Acute myeloid leukaemia [2A60] [87]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Arn-509. Acute myeloid leukaemia [2A60] [85]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [81]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Oliceridine. Acute pain [MG31] [80]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Lapatinib and Ivabradine. Angina pectoris [BA40] [81]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Lapatinib and Dronedarone. Angina pectoris [BA40] [80]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Lapatinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [88]
Posaconazole DMUL5EW Major Decreased metabolism of Lapatinib caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [85]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Levalbuterol. Asthma [CA23] [89]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Lapatinib and Pirbuterol. Asthma [CA23] [90]
Troleandomycin DMUZNIG Major Decreased metabolism of Lapatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [85]
Ag-221 DMS0ZBI Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [85]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Retigabine. Behcet disease [4A62] [80]
Cariprazine DMJYDVK Moderate Decreased metabolism of Lapatinib caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [81]
Erdafitinib DMI782S Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [91]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Lapatinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [92]
Macitentan DMP79A1 Moderate Decreased metabolism of Lapatinib caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [93]
PF-04449913 DMSB068 Moderate Decreased metabolism of Lapatinib caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [94]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Lapatinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [90]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [89]
Revefenacin DMMP5SI Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [95]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Indacaterol. Chronic obstructive pulmonary disease [CA22] [90]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Arformoterol. Chronic obstructive pulmonary disease [CA22] [90]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Lapatinib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [96]
Fidaxomicin DMFP6MV Minor Decreased clearance of Lapatinib due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [85]
Intedanib DMSTA36 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [97]
Drospirenone DM1A9W3 Moderate Decreased metabolism of Lapatinib caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [84]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Lapatinib caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [84]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Probucol. Coronary atherosclerosis [BA80] [80]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Lapatinib and Pasireotide. Cushing syndrome [5A70] [80]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Osilodrostat. Cushing syndrome [5A70] [81]
Ivacaftor DMZC1HS Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [98]
MK-8228 DMOB58Q Moderate Decreased metabolism of Lapatinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [84]
Rivaroxaban DMQMBZ1 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [99]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Lapatinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [100]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Lapatinib caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [96]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [80]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Lapatinib and Deutetrabenazine. Dystonic disorder [8A02] [101]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Ingrezza. Dystonic disorder [8A02] [102]
Cenobamate DMGOVHA Moderate Increased metabolism of Lapatinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [85]
Stiripentol DMMSDOY Moderate Decreased metabolism of Lapatinib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [81]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Lapatinib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [85]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Lapatinib and Cannabidiol. Epileptic encephalopathy [8A62] [81]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Lapatinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [103]
Tazemetostat DMWP1BH Moderate Increased metabolism of Lapatinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [85]
Solifenacin DMG592Q Moderate Decreased metabolism of Lapatinib caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [104]
Mirabegron DMS1GYT Minor Decreased metabolism of Lapatinib caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [105]
Dexlansoprazole DM1DBV5 Moderate Decreased absorption of Lapatinib due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [81]
Ripretinib DM958QB Moderate Decreased metabolism of Lapatinib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [85]
Sunitinib DMCBJSR Moderate Decreased metabolism of Lapatinib caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [84]
Avapritinib DMK2GZX Moderate Decreased metabolism of Lapatinib caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [81]
Digitoxin DMWVIGP Moderate Decreased metabolism of Lapatinib caused by Digitoxin mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [84]
Boceprevir DMBSHMF Major Decreased metabolism of Lapatinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [84]
Telaprevir DMMRV29 Major Decreased metabolism of Lapatinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [85]
GS-5885 DMSL3DX Moderate Decreased clearance of Lapatinib due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [106]
GS-9857 DMYU6P5 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [107]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Lapatinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [108]
MK-1439 DM215WE Minor Decreased metabolism of Lapatinib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [109]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Lapatinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [110]
Cobicistat DM6L4H2 Major Decreased metabolism of Lapatinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Etravirine DMGV8QU Moderate Increased metabolism of Lapatinib caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [80]
Darunavir DMN3GCH Moderate Decreased metabolism of Lapatinib caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Lapatinib and Mipomersen. Hyper-lipoproteinaemia [5C80] [111]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Lapatinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [80]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Lapatinib and BMS-201038. Hyper-lipoproteinaemia [5C80] [112]
Aliskiren DM1BV7W Moderate Decreased metabolism of Lapatinib caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [80]
Levamlodipine DM92S6N Moderate Decreased metabolism of Lapatinib caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [84]
Tolvaptan DMIWFRL Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [113]
Berotralstat DMWA2DZ Major Decreased clearance of Lapatinib due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [114]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Lapatinib caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [85]
Amobarbital DM0GQ8N Moderate Increased metabolism of Lapatinib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [85]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Lapatinib caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [115]
Quazepam DMY4D87 Moderate Decreased metabolism of Lapatinib caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [84]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Lapatinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [81]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Lapatinib and Phenolphthalein. Irritable bowel syndrome [DD91] [80]
Eluxadoline DMYZ0P1 Major Decreased clearance of Lapatinib due to the transporter inhibition by Eluxadoline. Irritable bowel syndrome [DD91] [81]
Naloxegol DML0B41 Minor Decreased metabolism of Lapatinib caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [116]
Pemigatinib DM819JF Moderate Decreased metabolism of Lapatinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [81]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Lapatinib and Crizotinib. Lung cancer [2C25] [117]
Brigatinib DM7W94S Moderate Decreased metabolism of Lapatinib caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [85]
Ceritinib DMB920Z Major Decreased metabolism of Lapatinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [85]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Lapatinib caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [118]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Lapatinib and Osimertinib. Lung cancer [2C25] [119]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Lapatinib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [120]
Capmatinib DMYCXKL Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [121]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Lapatinib and Selpercatinib. Lung cancer [2C25] [81]
Artesunate DMR27C8 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Artesunate. Malaria [1F40-1F45] [84]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Lapatinib and Hydroxychloroquine. Malaria [1F40-1F45] [122]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [81]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Lapatinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [123]
Idelalisib DM602WT Major Decreased metabolism of Lapatinib caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [85]
GDC-0199 DMH0QKA Major Decreased clearance of Lapatinib due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [85]
IPI-145 DMWA24P Moderate Decreased metabolism of Lapatinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [84]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Lapatinib caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [124]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Lapatinib caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [125]
Arry-162 DM1P6FR Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Arry-162. Melanoma [2C30] [85]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Lapatinib and Vemurafenib. Melanoma [2C30] [80]
Selumetinib DMC7W6R Moderate Decreased metabolism of Lapatinib caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [126]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and LGX818. Melanoma [2C30] [127]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Lapatinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [85]
Danazol DML8KTN Moderate Decreased metabolism of Lapatinib caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [84]
Ubrogepant DM749I3 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Ubrogepant. Migraine [8A80] [128]
Rimegepant DMHOAUG Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Rimegepant. Migraine [8A80] [129]
Lasmiditan DMXLVDT Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [130]
Exjade DMHPRWG Moderate Decreased metabolism of Lapatinib caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [131]
Flibanserin DM70DTN Moderate Decreased metabolism of Lapatinib caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [132]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Lapatinib and Panobinostat. Multiple myeloma [2A83] [133]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Lapatinib and Siponimod. Multiple sclerosis [8A40] [85]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Lapatinib and Fingolimod. Multiple sclerosis [8A40] [80]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Lapatinib and Ozanimod. Multiple sclerosis [8A40] [134]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Romidepsin. Mycosis fungoides [2B01] [80]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Lapatinib and Nilotinib. Myeloproliferative neoplasm [2A20] [80]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Lapatinib caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [81]
Rolapitant DM8XP26 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [135]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Entrectinib. Non-small cell lung cancer [2C25] [85]
S-297995 DM26IH8 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [81]
Olaparib DM8QB1D Moderate Decreased metabolism of Lapatinib caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [136]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Rucaparib. Ovarian cancer [2C73] [80]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Triclabendazole. Parasitic worm infestation [1F90] [80]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Pimavanserin. Parkinsonism [8A00] [137]
Abametapir DM2RX0I Moderate Decreased metabolism of Lapatinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [138]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Lapatinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [139]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Lapatinib and Lefamulin. Pneumonia [CA40] [140]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Lapatinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [85]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Degarelix. Prostate cancer [2C82] [81]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Lapatinib and ABIRATERONE. Prostate cancer [2C82] [81]
Enzalutamide DMGL19D Moderate Decreased metabolism of Lapatinib caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [85]
Relugolix DMK7IWL Major Decreased clearance of Lapatinib due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [141]
Darolutamide DMV7YFT Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [142]
Silodosin DMJSBT6 Moderate Decreased metabolism of Lapatinib caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [143]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Levomepromazine. Psychotic disorder [6A20-6A25] [80]
Selexipag DMAHSU0 Moderate Decreased metabolism of Lapatinib caused by Selexipag mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [144]
Riociguat DMXBLMP Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [85]
Everolimus DM8X2EH Moderate Decreased metabolism of Lapatinib caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [145]
Axitinib DMGVH6N Moderate Decreased metabolism of Lapatinib caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [81]
Temsirolimus DMS104F Moderate Decreased metabolism of Lapatinib caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [146]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Lapatinib and Iloperidone. Schizophrenia [6A20] [80]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Paliperidone. Schizophrenia [6A20] [80]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Lapatinib and Amisulpride. Schizophrenia [6A20] [147]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Asenapine. Schizophrenia [6A20] [80]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Lapatinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [84]
Tedizolid DMG2SKR Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [81]
LDE225 DMM9F25 Moderate Decreased metabolism of Lapatinib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [148]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Lapatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [81]
Larotrectinib DM26CQR Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [85]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Lapatinib caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [81]
Armodafinil DMGB035 Moderate Decreased metabolism of Lapatinib caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
LEE011 DMMX75K Major Decreased metabolism of Lapatinib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [80]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Lapatinib and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [80]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [81]
Pitolisant DM8RFNJ Moderate Increased metabolism of Lapatinib caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [81]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [80]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Lapatinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [149]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [150]
Eltrombopag DMOGFIX Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Eltrombopag. Thrombocytopenia [3B64] [151]
Apixaban DM89JLN Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [81]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Lenvatinib. Thyroid cancer [2D10] [80]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Lapatinib and Cabozantinib. Thyroid cancer [2D10] [81]
Saxagliptin DMGXENV Moderate Decreased metabolism of Lapatinib caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [81]
Elagolix DMB2C0E Moderate Increased metabolism of Lapatinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [85]
Fluticasone DMGCSVF Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Fluticasone. Vasomotor/allergic rhinitis [CA08] [84]
⏷ Show the Full List of 164 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sunset yellow FCF E00255 17730 Colorant
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Certolake sunset yellow E00351 61817 Colorant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lapatinib 250 mg tablet 250 mg Oral Tablet Oral
Lapatinib Ditosylate eq 250mg base tablet eq 250mg base Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
8 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
9 Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813.
10 The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
11 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
12 Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
13 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
24 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
25 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
26 Drug Interactions Flockhart Table
27 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
28 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
29 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
30 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
31 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
32 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
33 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
34 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
35 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
36 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
37 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
38 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
39 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
40 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
41 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
42 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
43 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
44 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
45 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
46 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
47 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
48 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
49 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
50 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
51 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
52 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
53 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
54 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
55 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
56 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
57 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
58 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
59 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
60 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
61 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
62 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
63 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
64 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
65 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
66 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
67 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
68 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
69 Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
70 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
71 Clinical pipeline report, company report or official report of Roche (2009).
72 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
73 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
74 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
75 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
76 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
77 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
78 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
79 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
80 Canadian Pharmacists Association.
81 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
82 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
83 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
84 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
85 Cerner Multum, Inc. "Australian Product Information.".
86 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
87 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
88 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
89 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
90 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
91 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
92 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
93 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
94 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
95 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
96 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
97 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
98 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
99 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
100 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
101 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
102 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
103 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
104 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
105 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
106 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
107 Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
108 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
109 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
110 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
111 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
112 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
113 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
114 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
115 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
116 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
117 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
118 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
119 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
120 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
121 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
122 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
123 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
124 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
125 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
126 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
127 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
128 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
129 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
130 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
131 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
132 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
133 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
134 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
135 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
136 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
137 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
138 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
139 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
140 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
141 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
142 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
143 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
144 Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
145 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
146 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
147 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
148 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
149 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
150 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
151 Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]